Targeted News Service

TZIELD Phase 3 Data Presented at ISPAD Shows Potential to Slow the Progression of Stage 3 Type 1 Diabetes in Newly Diagnosed Children and Adolescents
October 19, 2023

PARIS, France, Oct. 19 (TNSres) -- Sanofi, a life sciences company, issued the following news release on Oct. 18, 2023:

* * *

full data simultaneously published in The NEJM

* * *

TZIELD(R) Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine

* TZIELD met the study' . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form